| Title |
Cemented allograft-prosthesis composite reconstruction for the proximal femur tumor
|
|---|---|
| Published in |
OncoTargets and therapy, August 2015
|
| DOI | 10.2147/ott.s85788 |
| Pubmed ID | |
| Authors |
Li Min, Fan Tang, Hong Duan, Yong Zhou, Wen-li Zhang, Rui Shi, Chong-qi Tu |
| Abstract |
Cemented allograft-prosthesis composite (APC) reconstruction is one option following resection of the proximal femur tumor. However, rare studies have focused on the indications and complications. The goal of the present study was to (1) ascertain the indications for cemented APC arthroplasty in the proximal femur; (2) identify the detailed perioperative management; and (3) illustrate our experiences to avoid the complications of cemented APC. A total 28 patients who underwent cemented APC reconstruction of the proximal femur after tumor resection were retrospectively evaluated at a median follow-up of 56 months. Clinical records and radiographs were reviewed to evaluate patients' outcome. In our series, excluding three cases of death that had a short follow-up period, union occurred in 22 (88.0%) patients (range 9-18 months). Nonunion of the greater trochanter was seen in six of the 12 patients (50.0%). Eight (32.0%) hips had resorption. There were two (8.0%) hips that were observed to have asymptomatic wear of the acetabulum. The average Musculoskeletal Tumor Society (MSTS) score was 26.5 points. The average Harris Hip Score (HHS) score was 80.6 points. There were no cases of recurrence, but metastasis was found in two hips. Mastering indications, perioperative management, and complication prevention are all very important in the APC reconstruction after resection of the proximal femur. |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 23 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 17% |
| Student > Ph. D. Student | 4 | 17% |
| Student > Master | 3 | 13% |
| Student > Bachelor | 2 | 9% |
| Student > Postgraduate | 2 | 9% |
| Other | 2 | 9% |
| Unknown | 6 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 61% |
| Biochemistry, Genetics and Molecular Biology | 1 | 4% |
| Business, Management and Accounting | 1 | 4% |
| Engineering | 1 | 4% |
| Unknown | 6 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 August 2015.
All research outputs
#22,756,649
of 25,371,288 outputs
Outputs from OncoTargets and therapy
#2,078
of 3,016 outputs
Outputs of similar age
#236,277
of 276,409 outputs
Outputs of similar age from OncoTargets and therapy
#65
of 97 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 276,409 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 97 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.